These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

408 related items for PubMed ID: 15334630

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ, de Bruijn HW, Hollema H, ten Hoor KA, Willemse PH, Aalders JG, van der Zee AG.
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence.
    Alexander-Sefre F, Chandrakumaran K, Banerjee S, Sexton R, Thomas JM, Moran B.
    Colorectal Dis; 2005 Jul; 7(4):382-6. PubMed ID: 15932563
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baratti D, Kusamura S, Martinetti A, Seregni E, Laterza B, Oliva DG, Deraco M.
    Ann Surg Oncol; 2007 Aug; 14(8):2300-8. PubMed ID: 17510772
    [Abstract] [Full Text] [Related]

  • 7. [Antigens (CEA and CA 19-9) in diagnosis and prognosis colorectal cancer].
    Grotowski M.
    Pol Merkur Lekarski; 2002 Jan; 12(67):77-80. PubMed ID: 11957811
    [Abstract] [Full Text] [Related]

  • 8. Clinical utility of elevated tumor markers in patients with disseminated appendiceal malignancies treated by cytoreductive surgery and HIPEC.
    Ross A, Sardi A, Nieroda C, Merriman B, Gushchin V.
    Eur J Surg Oncol; 2010 Aug; 36(8):772-6. PubMed ID: 20561764
    [Abstract] [Full Text] [Related]

  • 9. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
    Ayhan A, Guven S, Guven ES, Kucukali T.
    Acta Obstet Gynecol Scand; 2007 Aug; 86(4):484-90. PubMed ID: 17486473
    [Abstract] [Full Text] [Related]

  • 10. Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer.
    Gasser M, Gerstlauer C, Grimm M, Bueter M, Lebedeva T, Lutz J, Maeder U, Ribas C, Ribas C, Nichiporuk E, Thalheimer A, Heemann U, Thiede A, Meyer D, Waaga-Gasser AM.
    Ann Surg Oncol; 2007 Apr; 14(4):1272-84. PubMed ID: 17211733
    [Abstract] [Full Text] [Related]

  • 11. The use of tumor markers as predictors of prognosis in gastric cancer.
    Mihmanli M, Dilege E, Demir U, Coskun H, Eroglu T, Uysalol MD.
    Hepatogastroenterology; 2004 Apr; 51(59):1544-7. PubMed ID: 15362797
    [Abstract] [Full Text] [Related]

  • 12. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
    Chen C, Chen LQ, Yang GL, Li Y.
    Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
    [Abstract] [Full Text] [Related]

  • 13. [Prognostic study of preoperative serum levels of CEA and CA 19-9 in colorectal cancer].
    Uehara M, Manaka D, Baba S, Oji Y, Hirata K, Shimizu M, Noguchi M.
    Gan To Kagaku Ryoho; 2007 Sep; 34(9):1413-7. PubMed ID: 17876139
    [Abstract] [Full Text] [Related]

  • 14. [Standards, options and recommendations for tumor markers in colorectal cancer].
    Eche N, Pichon MF, Quillien V, Gory-Delabaere G, Riedinger JM, Basuyau JP, Daver A, Buecher B, Conroy T, Dieu L, Bidart JM, Deneux L, Groupe de travail Nicole Eche (coordonnateur), oncobiologiste.
    Bull Cancer; 2001 Dec; 88(12):1177-206. PubMed ID: 11792611
    [Abstract] [Full Text] [Related]

  • 15. [Role of the tumor markers CA 19-9 and carcinoembryonic antigen (CEA) in diagnosis, treatment and prognosis of pancreatic cancer].
    Kokhanenko NIu, Ignashov AM, Varga EV, Polkanova MS, Aleshina LA, Kimbarovskaia AA, Osipenko SK, Lebedev EG.
    Vopr Onkol; 2001 Dec; 47(3):294-7. PubMed ID: 11544826
    [Abstract] [Full Text] [Related]

  • 16. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
    Lai IR, Lee WJ, Huang MT, Lin HH.
    Hepatogastroenterology; 2002 Dec; 49(46):1157-60. PubMed ID: 12143226
    [Abstract] [Full Text] [Related]

  • 17. Significance of serum tumor markers carcinoembryonic antigen, CA 19-9, CA 125, and CA 15-3 in pre-orthotopic liver transplantation evaluation.
    Pissaia A, Bernard D, Scatton O, Soubrane O, Conti F, Calmus Y.
    Transplant Proc; 2009 Mar; 41(2):682-4. PubMed ID: 19328956
    [Abstract] [Full Text] [Related]

  • 18. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P.
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [Abstract] [Full Text] [Related]

  • 19. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer.
    Schneider J, Schulze G.
    Anticancer Res; 2003 Mar; 23(6D):5089-93. PubMed ID: 14981971
    [Abstract] [Full Text] [Related]

  • 20. Diagnostic value of serum tumor markers in asymptomatic individuals.
    Eleftheriadis N, Papaloukas C, Pistevou-Gompaki K.
    J BUON; 2009 Mar; 14(4):707-10. PubMed ID: 20148467
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.